- Home
- ATLC vs KROS Comparison
ATLC vs KROS Comparison
Compare ATLC & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ATLC | KROS |
|---|---|---|
| Founded | 1996 | 2015 |
| Country | United States | United States |
| Employees | 417 | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 726.2M | 584.9M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | ATLC | KROS |
|---|---|---|
| Price | $54.81 | $10.91 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 8 |
| Target Price | ★ $88.67 | $22.25 |
| AVG Volume (30 Days) | 58.4K | ★ 415.8K |
| Earning Date | 03-12-2026 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 146.00 |
| EPS | N/A | ★ 2.30 |
| Revenue | N/A | ★ $243,864,000.00 |
| Revenue This Year | $472.00 | N/A |
| Revenue Next Year | $7.66 | $727.07 |
| P/E Ratio | $9.74 | ★ $4.83 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $42.03 | $9.12 |
| 52 Week High | $78.91 | $22.55 |
Technical Indicators
Market Signals| Indicator | ATLC | KROS |
|---|---|---|
| Relative Strength Index (RSI) | 50.17 | 22.11 |
| Support Level | $53.43 | $10.49 |
| Resistance Level | $58.10 | $15.21 |
| Average True Range (ATR) | 3.51 | 0.66 |
| MACD | 0.10 | 0.03 |
| Stochastic Oscillator | 58.12 | 6.56 |
Price Performance
Historical ComparisonAbout ATLC Atlanticus Holdings Corporation
Atlanticus Holdings Corp invests in the financial services industry. It provides various credit and related financial services and products to or associated with the financially underserved consumer credit market. The operating business segments are the Credit as a Service (CaaS) and the Auto Finance segment. It generates maximum revenue from the Credit as a Service segment.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.